GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS

Core Viewpoint - Glucotrack, Inc. has appointed Andy Balo to its Board of Directors to enhance its efforts in developing and commercializing continuous blood glucose monitoring technology for diabetes patients [1][5]. Company Overview - Glucotrack, Inc. is focused on designing, developing, and commercializing novel technologies specifically for people with diabetes [6]. - The company is currently working on a long-term implantable continuous blood glucose monitoring system that aims to improve the management of diabetes [6][7]. Appointment of Andy Balo - Andy Balo brings over 20 years of experience in the medical technology industry, having previously served as Executive Vice President at Dexcom, where he played a key role in regulatory submissions and clinical trials [2][3]. - Balo has a strong background in regulatory and clinical strategies, having been involved in the approval of over 100 medical devices, including continuous glucose monitors [3][4]. - His expertise is expected to be invaluable as Glucotrack moves into human clinical studies for its innovative technology [5]. Product Details - Glucotrack's continuous blood glucose monitor (CBGM) is designed to be a long-term, implantable system that measures blood glucose levels continuously, with a sensor longevity of over 2 years and minimal calibration required [7].